Madhu Sanga

A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring <i>KMT2A</i> or <i>NPM1</i> Alterations

Elias Jabbour, Emma Searle, Maher Abdul‐Hay et al. · Blood · 2023 · 42 citations

An open-label, single-dose, phase 1 study of the absorption, metabolism and excretion of quizartinib, a highly selective and potent FLT3 tyrosine kinase inhibitor, in healthy male subjects, for the treatment of acute myeloid leukemia

Madhu Sanga, Joyce James, Joseph Marini et al. · Xenobiotica · 2016 · 31 citations

Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with <i>KMT2A</i> and <i>NPM1</i> Alterations

Emma Searle, Christian Récher, Maher Abdul‐Hay et al. · Blood · 2024 · 25 citations

Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with <i>KMT2Ar</i> or <i>NPM1</i> Alterations

Christian Récher, Jenny O’Nions, Ibrahim Aldoss et al. · Blood · 2024 · 21 citations · Full text

Pharmacokinetics, metabolism, and excretion of nefopam, a dual reuptake inhibitor in healthy male volunteers

Madhu Sanga, John Banach, Aaron R. Ledvina et al. · Xenobiotica · 2016 · 18 citations

Pharmacotherapy, Experimental Pharmacology, Molecular Pharmacology +17